Early Results Suggest Opdivo Combo May Help People with Advanced Pancreatic Cancer
News
Adding cabiralizumab to Opdivo (nivolumab) induced durable clinical benefit in heavily treated pancreatic cancer patients, a group largely insensitive to immunotherapy, early results from an ongoing Phase 1a/1b trial ... Read more